Press Enter to search · Esc to close
A phase 3 trial of a glucagon/GLP-1 dual agonist lands alongside a semaglutide biosimilar and new cardiometabolic signals — incretin therapy is outgrowing the obesity box.
Endocrinologists are quietly rewriting the rulebook — treating diabetes, fatty liver, and heart disease as one slow-burning inflammatory story. Here's what that means for the rest of us.
The same drugs reshaping body composition are now generating clinical surprises in both directions — including a side effect nobody saw coming.
A multi-omics study of Greek Orthodox practitioners suggests that cycling off animal products — even briefly — quietly rewires the blood chemistry linked to cardiometabolic risk.
Semaglutide-class drugs are rewriting cardiometabolic medicine — and quietly accumulating a safety file that gym-goers should actually read.
A 2025 GeroScience synthesis pulls together decades of flaxseed research — and the lipid, pressure, and glycemic signals are more durable than the supplement aisle suggests.
A 2025 meta-analysis of 29 randomized trials suggests GLP-1 receptor agonists trim cardiovascular events in non-diabetic adults with obesity — while parallel reviews push the class into PCOS, perioperative care, and an experimental dual-receptor frontier.